TYK2 and prostate carcinoma: Similarly, in prostate cancer cells, inhibition of TYK2 gene expression by shRNA decreases invasion through decreased urokinase-type plasminogen activator (uPA), which is involved in the activation of MMPs that degrade extracellular matrix proteins [114,127].